Hair loss pipeline looking thicker as investors plough $270 million into a cure for balding

The race to find a new treatment for hair loss hotted up last month with two mega funding rounds for Pelage Pharmaceuticals and Veradermics. The deals also demonstrated biopharma’s growing interest in consumer-focused prescription products.

There is no denying the impact GLP-1s have had on the pharmaceutical industry, Eli Lilly (NYSE: LLY) is currently on track to hit a market capitalization of $1 trillion largely due to Mounjaro/Zepbound (tirzepatide).

So, it is unsurprising investors are keen to find products that emulate this successful formula of meeting the clinical and aesthetic needs of an increasingly image conscious public. With some of the air coming out of the obesity market, hair loss could be an ideal investment area.